University of Iowa Health Care is among the first sites in the country to participate in a phase 3 clinical trial to test a new, personalized vaccine for patients with high-risk melanoma. The study will combine individualized mRNA vaccines with the immunotherapy pembrolizumab to determine if the combination is safe and does a better job than pembrolizumab alone at preventing melanoma from…